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Abstract 
Objective 
We sought to characterise C9orf72 expansions in relation to genetic ancestry and 
age at onset (AAO), and to use these parameters to discriminate the behavioural 
from the language variant syndrome, in a large pan-European cohort of 
frontotemporal lobar degeneration (FTLD) cases. 
Methods 
We evaluated expansions frequency in the entire cohort (n=1396; bvFTD [n=800], 
PPA [n=495] and FTLD-MND [n=101]). We then focused on the bvFTD and PPA 
cases and tested for association between expansion status, syndromes, genetic 
ancestry, and AAO applying statistical tests comprising Fisher’s Exact, ANOVA with 
Tukey post-hoc tests, and logistic and non-linear mixed-effects model regressions. 
Results 
We found C9orf72 pathogenic expansions in 4% of all cases (56/1396). Expansion 
carriers differently distributed across syndromes: 12/101 FTLD-MNDs (11.9%), 
40/800 bvFTDs (5%) and 4/495 of PPAs (0.8%). While addressing population-
substructure through principal component analysis (PCA), we defined 2 patients 
groups with Central/Northern (n=873) and Southern European (n=523) ancestry.  
The proportion of expansion carriers was significantly higher in bvFTDs compared to 
PPAs (5% vs. 0.8% [p=2.17x10-5; OR=6.4; CI:2.31-24.99]), as well as in individuals 
with Central/Northern European compared to Southern European ancestry (4.4% vs. 
1.8% [p=1.1x10-2; OR=2.5; CI:1.17-5.99]). Pathogenic expansions and 
Central/Northern European ancestry independently and inversely correlated with 
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 AAO. Our prediction model (based on expansions status, genetic ancestry and AAO) 
predicted a diagnosis of bvFTD with 64% accuracy. 
Conclusions Our results indicate correlation between pathogenic C9orf72 
expansions, AAO, PCA-based Central/Northern European ancestry and a diagnosis 
of bvFTD, implying to complex genetic risk-architectures differently underpinning the 
behavioural and language variant syndromes.
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 Introduction 
Frontotemporal lobar degeneration (FTLD) refers to the second most common form 
of young-onset dementia after Alzheimer’s Disease (AD) 1. The major clinical 
syndromes are behavioural variant (bvFTD) 2 and/or language dysfunctions, broadly 
called primary progressive aphasia (PPA); the latter is subdivided in semantic 
dementia (SD) (or semantic variant PPA) and progressive non-fluent aphasia 
(PNFA) (or nonfluent/agrammatic variant PPA) 2, 3. FTLD can also occur together 
with motor neuron disease (FTLD-MND, or amyotrophic lateral sclerosis [FTLD-
ALS]) in a continuous spectrum of phenotypes 4.  
In FTLD, repeat expansions in C9orf72 5 have been previously reported to occur in 
~25% 6-10 of familial and ~6% 11 of sporadic cases (i.e. individuals with no clear 
familial history and/or genetic aetiology 12). Several studies had shown high 
frequencies of pathogenic C9orf72 expansions in Northern vs. Southern European 
patients (North-South axis), especially in historically isolated populations (such as 
the Finnish 13, 14), leading to the hypothesis that a Scandinavian founder might be at 
the basis of the spread of the C9orf72 expansion 15. Other studies (based on the 
geographical location of the recruiting sites) challenged the North-South axis concept 
either reporting a high frequency (~25%) of pathogenic expansions in the Spanish 
population 10, or implying to the existence of more than one risk-haplotype 16-19. 
FTLD patients with abnormal C9orf72 repeat expansions exhibit marked 
phenotypical and pathological heterogeneity, thus suggesting presence of additional 
(genetic and environmental) modifiers 20. Despite conflicting studies reporting either 
direct or inverse correlation between repeat length and age at onset (AAO), C9orf72 
expansions have been suggested to act as a genetic modifier of AAO 16, 21-24. 
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 We here analysed 1396 FTLD cases gathered through the IFGC (International FTD-
Genetics Consortium; https://ifgcsite.wordpress.com/) phase-III initiative, aiming at (i) 
characterising C9orf72 expansions in relation to genetic ancestry and AAO, and (ii) 
assessing the usefulness of these parameters in discriminating the behavioural from 
the language variant syndrome.  
 
Methods 
Cohort, clinical phenotyping 
FTLD cases were collected between 2016 and 2018 (within the IFGC phase-III 
project [https://ifgcsite.wordpress.com/ongoing-projects/]). The samples were 
recruited by clinicians and research groups who are part of the IFGC network and 
based in Italy, Spain, Germany, the Netherlands, Belgium, UK, Sweden, Norway, 
Slovenia, and USA (Supplementary Table 1: https://doi.org/10.5522/04/12418157). 
Patients were diagnosed at each contributing site (Supplementary Table 2: 
https://doi.org/10.5522/04/12418157) in a harmonised fashion according to international 
consensus criteria such as the Neary et al (for FTLD), Rascovsky et al (for bvFTD), 
Gorno-Tempini et al (for PPA [SD or PNFA]) and Strong et al (for FTLD-MND) 
criteria 2-4, 25.  
Genotyping, C9orf72 repeat expansions and analysis cohorts 
Thousand four-hundred and fifty-four (1454) cases were successfully genotyped by 
means of the NeuroArray 26 on the Illumina Infinium platform. Genotypes were used 
to inform on population substructure via standard principal component analysis 
(PCA) (Supplementary Figure 1: https://doi.org/10.5522/04/12418157), which led to 
the exclusion of 44 population outliers, and allowed to address population-
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 substructure within the cohort (we identified 2 distinct [‘Nordic’ and ‘Mediterranean’] 
clusters; Supplementary Figure 2: https://doi.org/10.5522/04/12418157). We also 
assessed cryptic relatedness and excluded 14 first or second degree related 
individuals, leaving a cohort of 1396 cases (group 0) – for which C9orf72 expansion 
status (i.e. presence/absence of pathogenic expansions) was known – for analyses. 
Frequencies of pathogenic expansions were assessed in group 0 and further 
analyses were performed in: i) 1295 cases (group 1: n = 800 bvFTDs and n = 495 
PPAs) with known C9orf72 expansion status; ii) 1179 cases (group 2; n = 756 
bvFTDs and n = 423 PPAs) with known C9orf72 expansion status and age at onset 
(AAO) data available, and; iii) 734 cases (group 3; n = 462 bvFTDs and n = 272 
PPAs) with AAO and repeat counts (rc; screened via repeat-primed PCR [RP-PCR] 
[c.f. 27, 28], see Supplementary Materials and Methods and Supplementary Figure 
3: https://doi.org/10.5522/04/12418157) data available (Figure 1A).   
Statistical analyses 
We first assessed the frequency of pathogenic expansions in the entire cohort (group 
0). The information on presence/absence of expansions was used as a binary 
variable (0 = absence of expansion; 1 = presence of expansion). We then 
investigated differences in the frequencies of pathogenic expansions across bvFTDs 
and PPAs, and the ‘Nordic’ and ‘Mediterranean’ clusters in group 1 (Fisher’s Exact 
test) and in group 3 (logistic regression); in the latter, we used repeat counts (rc) as 
a categorical variable (using ‘no’, ‘short’, ‘intermediate’ and ‘long’ as factor levels) 
considering the following 4 categories: ‘no’ expansions (rc = 2/3), ‘short’ expansions 
(4 ≤ rc ≤ 8), ‘intermediate’ expansions (9 ≤ rc ≤ 24) and ‘long’ expansions (rc ≥ 25), 
the latter representing expansions in the pathogenic range (c.f. 10, 22; see also 
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 Supplementary Materials and Methods and Supplementary Figure 3: 
https://doi.org/10.5522/04/12418157).  
We then evaluated association between AAO and syndrome, genetic ancestry and 
expansions (i.e. presence/absence used as a binary variable, see above) alone and 
with genetic ancestry as a covariate in group 2 (t-test and logistic regression) and in 
group 3 (t-test, ANOVA with Tukey post-hoc test, and logistic and linear mixed-
effects model). In the latter case, we used rc as a categorical variable (see above). 
Finally, we sought to build a model to predict syndrome (bvFTD vs. PPA) using (i) 
presence/absence of pathogenic expansions (as binary variable [see above] for 
group 2) or (ii) rc (as categorical variable [see above] for group 3), ancestry as binary 
variable and AAO as continuous variable using logistic regression models (i.e. the 
leave-one-out cross validation [LOOCV] and the K-fold models). A summary of the 
analyses workflow can be found in Figure 1B. 
All analyses were performed using R studio (version 3.6.0, studio version 1.2.1335).  
C9orf72 locus risk-haplotype  
Twenty (rs1110264, rs1110155, rs2150336, rs1161680, rs2589054, rs1822723, 
rs4879515, rs895023, rs868856, rs1977661, rs903603, rs12349820, rs10122902, 
rs2282241, rs1948522, rs1982915, rs2453556, rs702231, rs696826 and rs247751) 
of the original 42 SNPs constituting the (Finnish) risk-haplotype 29 were available on 
the NeuroArray 26. We filtered out 7 markers in order to keep 13 informative SNPs 
(rs1822723, rs4879515, rs868856, rs1977661, rs903603, rs10122902, rs2282241, 
rs1948522, rs1982915, rs2453556, rs702231, rs696826, rs2477518) matching 13 of 
the 20 used in Mok et al 15. We evaluated the proportion of cases carrying at least 
one risk-allele (as in Mok et al 15) for each marker assessing expansion vs. non-
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 expansion carriers (with/without ancestry stratification).  
Standard Protocol Approvals, Registrations and Patient Consents 
Each contributing site obtained written informed consent from all patients to be part 
of extended genetic studies; the current study is approved under Institutional Review 
Board (IRB),approval #9811/001. 
Data availability 
All data generated or analysed during this study are included in this published article (and 
Supplementary files 1 and 2 at: https://doi.org/10.5522/04/12418157. 
 
Results 
C9orf72 expansions frequency and syndromes 
We assessed the frequency of pathogenic expansions in the entire cohort and 
across the different syndromes in the group 0 cases (Figure 1). Four percent of all 
cases (56/1396 [4%]) carried pathogenic expansions. These were most frequent in 
FTLD-MNDs (12/101 [11.9%]) followed by bvFTDs (40/800 [5%]) and PPAs (4/495 
[0.8%]). The higher prevalence of pathogenic expansions in bvFTDs vs. PPAs was 
statistically significant (Fisher’s Exact test: p = 2.17x10-5; OR = 6.4; 95% CI: 2.31 – 
24.99 Table 1). We further explored this finding in the group 3 cases using logistic 
regression to assess association between expansion length (represented by 4 repeat 
counts [rc] factor levels – ‘short’, ‘intermediate’ and ‘long’ expansions, tested against 
‘no’ expansions) and syndromes (bvFTD vs. PPA). Expansion length discriminated 
bvFTD from PPA with a trend that was significant in the ‘intermediate’ (p = 4.7x10-2; 
OR = 1.6; CI: 0.0061 [2.5%] – 0.94 [97.5%]) and ‘long’ (p = 1.9x10-3; OR = 7.2; CI: 
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 0.86 [2.5%] – 3.45 [97.5%]) rc ranges (with a ~90% probability of a bvFTD diagnosis 
supported by the latter; Supplementary Table 3 
https://doi.org/10.5522/04/12418157). 
C9orf72 expansions (and repeat counts [rc]) and genetic ancestry  
We performed PCA (PC1 vs. PC2, Supplementary Figure 2A; PC1 vs. PC3, 
Supplementary Figures 2B: https://doi.org/10.5522/04/12418157) to cluster the 
group 1 cases based on their genetic make-up. There were 2 major clusters: cluster-
1 (‘Mediterranean’) included most of the cases (439/500 [87.8%]) recruited from 
Southern European sites (Italy and Spain); cluster-2 (‘Nordic’) included most of the 
cases (627/795 [78.8%]) recruited from Central and Northern European sites 
(Belgium, The Netherlands, Germany, UK, Norway and Sweden). Samples recruited 
from Eastern European (Slovenia) and North American sites distributed across both 
clusters – although with a higher prevalence within cluster-2 (167/795 [21%]) vs. 
cluster-1 (42/500 [8.4%]). 
We observed a significantly higher prevalence of pathogenic expansions in the 
‘Nordic’ (35/795 [4.4%]) vs. the ‘Mediterranean’ (9/500 [1.8%]) cluster (Fisher’s Exact 
test: p = 1.1x10-2; OR = 2.5; CI: 1.17 – 5.99 Table 2). We further evaluated this 
finding in the group 3 cases using logistic regression to assess association between 
expansion length (see above) and genetic ancestry. Expansion length discriminated 
the ‘Nordic’ from ‘Mediterranean’ cluster with a trend that was significant in the 
‘intermediate’ (p = 9.7x10-4, OR = 2.2; CI: 0.32 [2.5%] – 1.25 [97.5%]) and ‘long’ (p = 
4.7x10-4, OR = 9.3; CI: 1.12 [2.5%] – 3.7 [97.5%]) rc ranges (with a ~90% probability 
of ‘Nordic’ ancestry supported by the latter; Supplementary Table 4: 
https://doi.org/10.5522/04/12418157). 
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 Provided differences in syndromes prevalence and distribution across the ‘Nordic’ 
and ‘Mediterranean’ clusters – bvFTD (469/795 [59%] vs. 331/500 [66.2%]) and PPA 
(326/795 [41%] vs. 169/500 [33.8%]), respectively (Supplementary Table 5: 
https://doi.org/10.5522/04/12418157) – we analysed the distribution of pathogenic 
expansions across syndromes and clusters. Stratified Fisher’s Exact test showed 
significant differences in the distribution of the pathogenic expansions between 
bvFTD and PPA in the’ Nordic’ (but not the ‘Mediterranean’) cluster (p = 1x10-4; OR = 
7.87; 95% CI: 2.43 – 40.52), and between the ‘Nordic’ and the ‘Mediterranean’ clusters 
for the bvFTD (but not PPA) syndrome (p = 1.9x10-2; OR = 2.95; 95% CI: 1.31 – 7.52), 
suggesting that ancestry (‘Nordic’) and syndrome (bvFTD) are independently 
associated with pathogenic expansions (Table 3). 
C9orf72 repeat expansions (and counts [rc]) and age at onset (AAO) 
We assessed AAO in the group 2 cases (Figure 1). Mean AAO was significantly 
different between the bvFTD (61.7) and PPA (64) syndromes (t-test: p = 1.86x10-5; 
CI: -3.34 – -1.25), and the ‘Nordic’ (61.3) and ‘Mediterranean’ (64.3) clusters (t-test: 
p = 1.16x10-7; CI: 1.86 – 4.03) (Supplementary Table 6A and B; Figure 2A: 
https://doi.org/10.5522/04/12418157). We then assessed the relationship between 
pathogenic expansions and AAO via logistic regression. First, we identified a 
significant correlation between a decrease in AAO and presence of pathogenic 
expansions (p = 7.7x10-4; R2 = 0.008; CI: -8.05 [2.5%] – -2.13 [97.5%]). When we 
included genetic ancestry in the model we observed a significant correlation with a 
decrease in AAO, no difference in using either cluster (p = 2.3x10-3; CI: -7.5 [2.5%] – 
-1.63 [97.5%] for pathogenic expansions; p = 2.3x10-7 ; CI: -3.9 [2.5%] – -1.77 
[97.5%] for cluster; R2=0.03) or PC1 (p = 2.1x10-3; CI: -7.5 [2.5%] – -1.66 [97.5%] for 
pathogenic expansions; p = 6.4x10-7; CI: 30.1 [2.5%] – 68.9 [97.5%] for PC1; 
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 R2=0.028) as covariate and an almost 4-fold goodness of fit increase 
(Supplementary Table 7A, B and C: https://doi.org/10.5522/04/12418157). Of note, 
when comparing the two regression models (with/without genetic ancestry as 
covariate) through the log-likelihood R2 ratio test, the difference (between the 2 
models) appeared not to be not due to chance (p < 10-12) (Supplementary Table 7B 
and C: https://doi.org/10.5522/04/12418157). 
We further evaluated the relationship between expansion length (represented by 4 
repeat counts [rc] factor levels – ‘short’, ‘intermediate’ and ‘long’ expansions, tested 
against ‘no’ expansions) and AAO in the group 3 cases (Figure 1). First, we 
independently analysed association between AAO and: i) genetic ancestry – mean 
AAO 60.9 and 64.6 in the ‘Nordic’ and ‘Mediterranean’ cluster, respectively (t-test: p 
= 2.1x10-7; CI: 2.32 – 5.09; Supplementary Table 8A: 
https://doi.org/10.5522/04/12418157); ii) syndrome – mean AAO 61.7 and 63.5 in the 
bvFTD and PPA syndromes, respectively (t-test: p = 9.1x10-3; CI: -3.11 – -0.44; 
Supplementary Table 8B: https://doi.org/10.5522/04/12418157), and; iii) expansion 
length – mean AAO 63.2 for both ‘no’ and ‘short’ expansions, 61 for ‘intermediate’ 
expansions and 58 for ‘long’ expansions (ANOVA: p = 3.6x10-2; CI: -10.2 – -0.23 for 
‘long’ vs. ‘no’ expansions) (Supplementary Table 8D; Figure 2B and C: 
https://doi.org/10.5522/04/12418157). We then assessed the relationship between 
expansion length (see above) and AAO via logistic regression. First, we identified a 
significant correlation between a decrease in AAO and both ‘intermediate’ and ‘long’ 
expansions (p = 4x10-2; CI: -4.36 [2.5%] – -0.96 [97.5%] for ‘intermediate’ and p = 
7x10-3; CI: -9.05 [2.5%] – -1.43 [97.5%] for ‘long’ expansions; R2 = 0.017) 
(Supplementary Table 9A: https://doi.org/10.5522/04/12418157). When we 
included genetic ancestry in the model we observed a significant correlation with a 
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 decrease in AAO, no difference in using either cluster (p = 4.7x10-2; CI: -7.65 [2.5%] 
– -0.05 [97.5%] for ‘long’ vs. ‘no’ expansion; p = 2.38x10-6; CI: -4.73 [2.5%] – -1.97 
[97.5%] for cluster; R2 = 0.045) or PC1 (p = 5.98x10-2; CI: -7.5 [2.5%] – 0.14 [97.5%] 
for ‘long’ vs. ‘no’ expansion; p = 1.2x10-6; CI: 39.8 [2.5%] – 92.9 [97.5%] for PC1; 
R2=0.047) as covariate and an almost 3-fold goodness of fit increase 
(Supplementary Table 9A, B and C: https://doi.org/10.5522/04/12418157). Of note, 
when comparing the two regression models (with/without genetic ancestry as 
covariate) through the log-likelihood R2 ratio test, the difference (between the 2 
models) appeared not to be due to chance (p < 10-12) (Supplementary Table 9B 
and C: https://doi.org/10.5522/04/12418157). These findings were further supported 
by non-linear mixed-effects model regression using genetic ancestry as random 
effect covariate (for ‘long’ vs. ‘no’ expansion; see Supplementary Table 10: 
https://doi.org/10.5522/04/12418157). 
C9orf72 locus risk-haplotype 
All of the risk alleles for the 13 markers – shortest informative stretch of the original 
risk-haplotype 15, 29 available to us – were seen in: i) 40/56 (71.4%) expansion 
carriers vs. 380/1340 (28.4%) non-expansion carriers in the entire cohort; ii) 33/47 
(70.2%) expansion carriers vs. 228/826 (27.6%) non-expansion carriers in the 
‘Nordic’ cluster, and; iii) 7/9 (77.8%) expansion carriers vs. 152/514 (29.6%) non-
expansion carriers in the ‘Mediterranean’ cluster. Comparing the proportion of risk-
allele carriers (expansion vs. non-expansion carriers) for each single marker, 5/13 
markers (rs4879515, rs868856, rs903603, rs2282241, rs2453556) were significant in 
the ‘Nordic’ cluster, none in the ‘Mediterranean’ cluster (Supplementary Figure 4: 
https://doi.org/10.5522/04/12418157). Rs2477518 showed variable frequencies for 
the risk-allele (T) across expansion vs. non-expansion carriers (and the 2 clusters), 
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 thus making this most probably a negligible marker within this stretch, as hinted 
previously 15, 17. Rs3849942, previously suggested as surrogate marker for the risk 
haplotype 15, was not among the SNPs available to us. We used rs868856, 
displaying strongest LD with rs3849942 (D’=0.96; R2=0.7; https://ldlink.nci.nih.gov/), 
as informative proxy: the risk-allele segregated differently across expansion vs. non-
expansion carriers in the ‘Nordic’ and ‘Mediterranean’ cluster (as  for rs2453556) 
possibly suggesting these 2 as the most conserved markers of the original risk-
haplotype across populations in expansion carriers (highlighted in blue in 
Supplementary Figure 4: https://doi.org/10.5522/04/12418157). 
Syndrome prediction 
We then sought to build a model to predict syndrome (bvFTD vs. PPA) and assess 
its accuracy. We analysed both groups 2 and 3 cases using expansion status 
(presence/absence of expansion for group 2, and the 4 rc factor levels for group 3 
[see materials and methods]), genetic ancestry (using either ‘cluster’ or ‘PC1’) as 
binary variables, and AAO as a continuous variable in logistic regression models. We 
observed an accuracy of ~0.64 (group 2; Supplementary Table 11: 
https://doi.org/10.5522/04/12418157) and ~0.62 (group 3; Supplementary Table 12: 
https://doi.org/10.5522/04/12418157) in predicting bvFTD, whilst there were no 
differences in the outcome when using either ‘cluster’ or ‘PC1’ as covariates in both 
(LOOCV and K-fold) models.AC
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Discussion 
This study aimed to characterise C9orf72 expansions in relation to genetic ancestry 
and age at onset (AAO), and to assess the usefulness of these parameters in 
discriminating the behavioural from the language variant syndrome, in a large pan-
European cohort of 1396 FTLD cases. 
To the best of our knowledge, the current work is unique in that, prior characterising 
the expansions, we excluded population-substructure bias using genome-wide 
genotyping data to cluster the cases on the basis of their genetic make-up. After 
principal component analysis (PCA) we identified two distinct clusters including 
samples with geographical ancestry corresponding to Southern Europe 
(‘Mediterranean’ cluster) and Central/Northern Europe (‘Nordic’ cluster). Our 
analyses not only showed that patients from the ‘Nordic’ cluster presented 
significantly higher frequency of pathogenic C9orf72 expansions compared to the 
‘Mediterranean’ cluster, but also that a core stretch of markers (n = 8) of the Finnish 
risk haplotype 29 appeared to be conserved across the ‘Nordic’ expansion carriers, 
whereas there was a similar tendency for (just) 2 of such markers in the 
‘Mediterranean’ expansion carriers. Several studies had shown high frequencies of 
long C9orf72 expansions in Northern vs. Southern European patients (North-South 
axis)13-15. Other studies (based on the geographical location of the recruiting sites) 
challenged the North-South axis concept 10, or the founder effect implying to the 
existence of more than one risk-haplotype 16-19. All this taken together, our current 
data appear to support the North-South axis hypothesis and suggest that 
rearrangements (and instability) 16, 19 at the C9orf72 locus might have occurred 
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 reducing the level of conservation of the original risk haplotype across the European 
population. 
We found pathogenic expansions in ~4% of all cases and that the proportion of 
expansion carriers was significantly higher in bvFTDs compared to PPAs. The fact 
that we overall identified significant association between pathogenic expansions and 
a diagnosis of bvFTD, and Central/Northern European ancestry – findings for the 
most in line with previous reports 8, 10, 13, 20, 30-34 – suggests that C9orf72 expansions 
might serve as useful genetic fingerprint to define subpopulations of FTLD patients 
(Figure 3). Of note, we observed a trend of association with syndrome (bvFTD) and 
genetic ancestry (Central/Northern European) already supported by the 
‘intermediate’ repeat counts (9 ≤ rc ≤ 24) category. This appears in line with previous 
reports suggesting that individuals with 7 to 24 alleles might have an increased risk 
to convert to carriers of pathological repeat expansions10, 22 and may, altogether, be 
useful information in the context of diagnostics. 
Despite some previous conflicting reports of direct (or inverse) correlation between 
C9orf72 expansions and AAO 16, 21, 23, we (as others 22, 24) found a significant inverse 
correlation between C9orf72 expansion length and AAO. Additionally, and 
interestingly, our data also indicates that Central/Northern European genetic 
ancestry contributes to a decreased AAO (independently from the expansions) 
possibly implying to a more complex genetic signature (or architecture), and 
subsequently molecular mechanisms, underpinning this very feature. Clearly, 
disease mechanisms that involve C9orf72 expansion length and AAO are complex, 
thus it is likely that additional factors might further modulate their relationship and 
effect on the phenotype (see also Babić Leko et al 5). 
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 While using expansion length, genetic ancestry and AAO in a regression model to 
discriminate behavioural from language variant subtypes, we found that such 
parameters did support a prediction of bvFTD with 64% accuracy. 
Our results have a number of implications. First, provided that significant variation 
exists in the genetic architecture of the Caucasian population 35, genetic variability 
characterising and differentiating ‘Nordic’ vs. ‘Mediterranean’ subjects (such as in the 
case of our cohort) might influence predisposition to harbouring longer repeat 
expansions. In other repeat expansion diseases – e.g. Huntington’s disease (HD) or 
other microsatellite diseases, including myotonic dystrophy and spinocerebellar  
ataxias 35 – the presence of specific haplogroups in Western European populations 
occurs with a manifold increase in prevalence of repeats compared to other ethnic 
groups and populations 36. Second, different genetic risk-architectures underpinning 
different (and possibly genetically more homogeneous) subpopulations of patients 
may exist within the FTLD population. 
In a nutshell, our results imply that a significantly higher proportion of FTLD cases, 
with ‘Nordic’ rather than ‘Mediterranean’ genetic ancestry, is likely to develop bvFTD 
in presence of  ‘intermediate’ and ‘long’ (pathogenic) expansions, whilst ‘long’ 
(pathogenic) expansions are (almost) negligible in PPAs, regardless of ancestry. 
Clearly, multiple factors including genetic heterogeneity, epigenetic changes, 
ethnicity, as well as environmental factors and habits that may subsist within and 
across multicultural cohorts, all together, contribute to disease predisposition, onset 
and progression 22, 37, 38. These concepts, reinforced by our study, warrant further 
characterisation of genetic, environmental, and additional clinical measures to fine-
tune models able to predict disease outcome to complement diagnostic criteria, and 
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 possibly assist, in the near future, in the identification of informative cohorts for 
tailored clinical trials and the development of effective personalised therapies.  
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Appendix 1: Authors 
      
Name Location Contribution 
Beatrice Costa, 
BSc 
University College London, Institute of 
Neurology, London, UK 
C9orf72 expansions 
screening; data 
interpretation and drafting of 
manuscript 
Claudia Manzoni, 
PhD 
School of Pharmacy, University College 
London, London, UK 
Project design; data 
analyses and interpretation; 
manuscript drafting 
Manuel Bernal-
Quiros, PhD 
Neurogenetics Laboratory, National Hospital 
for Neurology and Neurosurgery, London, UK 
C9orf72 expansions 
screening; data 
interpretation and drafting of 
manuscript 
Demis A Kia, MD University College London, Institute of Neurology, London, UK 
Data interpretation and 
drafting of manuscript 
Miquel Aguilar, 
MD Aptima Clinic, Terrassa, Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Ignacio Alvarez, 
MSc 
Memory Disorders Unit, Department of 
Neurology, University Hospital Mutua de 
Terrassa, Terrassa, Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Victoria Alvarez, 
PhD 
Hospital Universitario Central de Asturias, 
Oviedo, Asturias, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Ole A. 
AndreassenMD 
PhD 
NORMENT, Institute of Clinical Medicine, 
University of Oslo, Oslo, Norway 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Maria Anfossi, 
PhD 
Regional Neurogenetic Centre, ASPCZ, 
Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Silvia Bagnoli, 
PhD 
Department of Neuroscience, Psychology, 
Drug Research and Child Health, University of 
Florence, Florence, Italy  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Luisa Benussi, 
PhD 
Molecular Markers Laboratory, IRCCS Istituto 
Centro San Giovanni di Dio Fatebenefratelli, 
Brescia, Italy  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Livia Bernardi, 
PhD 
Regional Neurogenetic Centre, ASPCZ, 
Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Giuliano Binetti, 
MD 
Molecular Markers Laboratory, IRCCS Istituto 
Centro San Giovanni di Dio Fatebenefratelli, 
Brescia, Italy  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Daniel J. 
Blackburn, MD, 
PhD 
Sheffield Institute for Translational 
Neuroscience (SITraN), Department of 
Neuroscience, University of Sheffield, 
Sheffield, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Mercè Boada, 
MD, PhD 
Research Center and Memory Clinic. Fundació 
ACE. Institut Català de Neurociències 
Aplicades, Universitat Internacional de 
Catalunya (UIC). Barcelona, Spain. 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Barbara Borroni, 
MD 
Centre for Neurodegenerative Disorders, 
Department of Clinical and Experimental 
Sciences, University of Brescia, Brescia, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Lucy, Bowns Department of Clinical Neurosciences, Cambridge University, Cambridge, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Geir Bråthen, MD, 
PhD 
Department of Neurology, University Hospital 
of Trondheim, Trondheim, Norway 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Amalia C. Bruni, 
MD 
Regional Neurogenetic Centre, ASPCZ, 
Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Huei-Hsin Chiang, 
PhD 
Karolinska Institutet, Dept NVS, Division of 
Neurogeriatrics, Bioclinicum, Solna, Sweden 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Jordi Clarimon, 
PhD 
Department of Neurology, IIB Sant Pau, 
Hospital de la Santa Creu i Sant Pau, 
Universitat Autònoma de Barcelona, 
Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Shuna Colville Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Maria E. Conidi, 
PhD 
Regional Neurogenetic Centre, ASPCZ, 
Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Tom E. Cope, 
PhD, MD 
Department of Clinical Neurosciences, 
Cambridge University, Cambridge, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Carlos Cruchaga, 
PhD 
NeuroGenomics and Informatics, Washington 
University, Department of Psychiatry, St. Louis, 
MO, USA 
Critical review of manuscript 
for intellectual content 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Chiara Cupidi, MD Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Maria Elena Di 
Battista, MD, PhD 
Cognitive Impairment Center, Local Health 
Authority n.2 Marca Trevigiana, Treviso, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Janine Diehl-
Schmid, MD 
Technical University of Munich, School of 
Medicine, Department of Psychiatry and 
Psychotherapy, Munich, Germany 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Monica Diez-
Fairen, MsC 
Memory Disorders Unit, Department of 
Neurology, University Hospital Mutua de 
Terrassa, Terrassa, Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Oriol Dols-Icardo, 
PhD 
Department of Neurology, IIB Sant Pau, 
Hospital de la Santa Creu i Sant Pau, 
Universitat Autònoma de Barcelona, 
Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Elisabetta 
Durante, PhD 
Immunohematology and Transfusional 
Medicine Service, Local Health Authority n.2 
Marca Trevigiana, Treviso, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Dušan Flisar, MD Department of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Francesca 
Frangipane, MD 
Regional Neurogenetic Centre, ASPCZ, 
Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Daniela 
Galimberti, PhD 
University of Milan, Dino Ferrari Center, Milan, 
Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Maura Gallo, PhD Regional Neurogenetic Centre, ASPCZ, Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Maurizio Gallucci, 
MD 
Cognitive Impairment Center, Local Health 
Authority n.2 Marca Trevigiana, Treviso, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Roberta Ghidoni, 
PhD 
Molecular Markers Laboratory, IRCCS Istituto 
Centro San Giovanni di Dio Fatebenefratelli, 
Brescia, Italy  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Caroline Graff, 
MD, PhD 
Karolinska Institutet, Dept NVS, Division of 
Neurogeriatrics, Bioclinicum, Solna, Sweden 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Jordan 
H.Grafman, PhD 
Cognitive Neuroscience Lab, Think and Speak 
Lab, Shirley Ryan AbilityLab, Chicago, IL, USA 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Murray Grossman, 
MD 
Department of Neurology, Perelman School of 
Medicine at the University of Pennsylvania, 
Philadelphia, PA, USA 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
John Hardy, PhD UCL Dementia Research Institute Wing 1.2 Cruciform Building, London, UK 
Critical review of manuscript 
for intellectual content 
Isabel Hernández, 
MD, PhD 
Research Center and Memory Clinic. Fundació 
ACE. Institut Català de Neurociències 
Aplicades, Universitat Internacional de 
Catalunya (UIC). Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Guy J.T. 
Holloway, MBBS, 
MRCPsych 
Royal Edinburgh Hospital, Edinburgh, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Edward D. Huey, 
MD 
Taub Institute for Research on Alzheimer's 
Disease and the Aging Brain, Columbia 
University, New York, NY, USA  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Ignacio Illán-Gala, 
MD, PhD 
Department of Neurology, IIB Sant Pau, 
Hospital de la Santa Creu i Sant Pau, 
Universitat Autònoma de Barcelona, 
Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Anna Karydas 
Department of Neurology, Memory and Aging 
Center, University of California, San Francisco, 
San Francisco, CA, USA 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Behzad 
Khoshnood, PhD 
Karolinska Institutet, Dept NVS, Division of 
Neurogeriatrics, Bioclinicum, Solna, Sweden 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Milica G. 
Kramberger, MD, 
PhD 
Department of Neurology, University Medical 
Center Ljubljana, Ljubljana, Slovenia 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Mark Kristiansen, 
PhD 
UCL Genomics, UCL Great Ormond Street 
Institute of Child Health, London, UK 
Critical review of manuscript 
for intellectual content 
Patrick A. Lewis, 
PhD 
The Royal Veterinary College, Department of 
Comparative Biomedical Sciences, London, UK 
Critical review of manuscript 
for intellectual content 
Alberto Lleó, MD, 
PhD 
Department of Neurology, IIB Sant Pau, 
Hospital de la Santa Creu i Sant Pau, 
Universitat Autònoma de Barcelona, 
Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
A
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Gaganjit K. 
Madhan 
UCL Genomics, UCL Great Ormond Street 
Institute of Child Health, London, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Raffaele Maletta, 
MD 
Regional Neurogenetic Centre, ASPCZ, 
Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Aleš Maver, MD, 
PhD 
Clinical Institute of Medical Genetics, University 
Medical Center Ljubljana, Ljubljana, Slovenia 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Manuel 
Menendez-
Gonzalez, MD, 
PhD 
Hospital Universitario Central de Asturias, 
Oviedo, Asturias, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Graziella Milan, 
MD 
Geriatric Center Frullone ASL Napoli 1 Centro, 
Napoli, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Bruce L. Miller, 
MD 
Department of Neurology, Memory and Aging 
Center, University of California, San Francisco, 
San Francisco, CA, USA  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Merel O. Mol Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Parastoo Momeni, 
PhD Rona Holdings, Silicon Valley, CA, USA 
Critical review of manuscript 
for intellectual content; 
contribution of metadata 
Sonia Moreno-
Grau, PhD 
Research Center and Memory Clinic. Fundació 
ACE. Institut Català de Neurociències 
Aplicades, Universitat Internacional de 
Catalunya (UIC). Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Christopher M. 
Morris, PhD 
Newcastle Brain Tissue Resource, Institute of 
Neuroscience, Newcastle University, 
Edwardson Building, Campus for Ageing and 
Vitality, Newcastle upon Tyne, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Benedetta 
Nacmias, PhD 
Department of Neuroscience, Psychology, 
Drug Research and Child Health, University of 
Florence, Florence, Italy  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Christer Nilsson, 
MD 
Department of Neurology, Skåne University 
Hospital, Malmö, Sweden 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Valeria Novelli, 
PhD 
Fondazione Policlinico Universitario A. Gemelli 
IRCCS, Rome, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
AC
EP
TE
D
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Linn Öijerstedt, 
MD 
Karolinska Institutet, Dept NVS, Division of 
Neurogeriatrics, Bioclinicum, Solna, Sweden 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Alessandro 
Padovani, MD 
Centre for Neurodegenerative Disorders, 
Department of Clinical and Experimental 
Sciences, University of Brescia, Brescia, italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Suvankar Pal, 
MBBS, MRCP, 
MD 
Anne Rowling Regenerative Neurology Clinic, 
University of Edinburgh, Edinburgh, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Yasmin 
Panchbhaya 
UCL Genomics, UCL Great Ormond Street 
Institute of Child Health, London, UK 
Critical review of manuscript 
for intellectual content 
Pau Pastor, MD, 
PhD 
Memory Disorders Unit, Department of 
Neurology, University Hospital Mutua de 
Terrassa, Terrassa, Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Borut Peterlin, 
MD, PhD 
Clinical Institute of Medical Genetics, University 
Medical Center Ljubljana, Ljubljana, Slovenia 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Irene Piaceri, PhD 
Department of Neuroscience, Psychology, 
Drug Research and Child Health, University of 
Florence, Florence, Italy  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Stuart Pickering-
Brown, PhD 
Division of Neuroscience & Experimental 
Psychology, The University of Manchester, 
Manchester, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Yolande A.L. 
Pijnenburg, MD, 
PhD 
Amsterdam University Medical Center, VU 
University Medical Center, Amsterdam, The 
Netherlands 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Annibale A. Puca, 
MD 
Cardiovascular Research Unit, IRCCS 
Multimedica, Milan, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Innocenzo 
Rainero, MD, PhD 
Neurology I, Department of Neuroscience, 
University of Torino, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Antonella 
Rendina, PhD 
NeurOMICS laboratory, Institute of 
Biochemistry and Cell Biology (IBBC), CNR 
Napoli, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Anna M.T. 
Richardson, 
FRCP 
Manchester Centre for Clinical Neurosciences, 
Salford Royal NHS Trust, Manchester, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
A
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Ekaterina 
Rogaeva, PhD 
Tanz Centre for Research in 
Neurodegenerative Diseases, University of 
Toronto, Toronto, ON, Canada 
Critical review of manuscript 
for intellectual content 
Boris Rogelj, PhD Department of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Sara Rollinson, 
PhD 
Division of Neuroscience & Experimental 
Psychology, The University of Manchester, 
Manchester, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Giacomina Rossi, 
PhD 
Division of Neurology V and Neuropathology; 
Fondazione IRCCS  Istituto Neurologico Carlo 
Besta, Milano, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Carola Roßmeier, 
MD 
Technical University of Munich, School of 
Medicine, Department of Psychiatry and 
Psychotherapy, Munich, Germany 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
James B. Rowe, 
PhD, MD 
Department of Clinical Neurosciences, 
Cambridge University, Cambridge, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Elisa Rubino, MD, 
PhD 
Neurology I, Department of Neuroscience, 
University of Torino, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Agustín Ruiz, MD, 
PhD 
Research Center and Memory Clinic. Fundació 
ACE. Institut Català de Neurociències 
Aplicades, Universitat Internacional de 
Catalunya (UIC). Barcelona, Spain 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Raquel Sanchez-
Valle, MD, PhD 
Alzheimer's disease and other cognitive 
disorders unit. Hospital Clínic of Barcelona. 
Barcelona (Spain) 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Sigrid B. Sando, 
PhD 
Department of Neurology, University Hospital 
of Trondheim, Trondheim, Norway 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Alexander F. 
Santillo, MD, PhD 
Clinical Memory Research Unit, Lund 
University, Lund, Sweden 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Jennifer Saxon Manchester Centre for Clinical Neurosciences, Salford Royal NHS Trust, Manchester, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Elio Scarpini, MD University of Milan, Dino Ferrari Center, Milan, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Maria Serpente, 
PhD 
University of Milan, Dino Ferrari Center, Milan, 
Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Nicoletta Smirne, 
BSc 
Regional Neurogenetic Centre, ASPCZ, 
Lamezia Terme, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Sandro Sorbi, MD 
Department of Neuroscience, Psychology, 
Drug Research and Child Health, University of 
Florence, Florence, Italy  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
EunRan Suh, PhD 
Department of Pathology and Laboratory 
Medicine, Perelman School of Medicine at the 
University of Pennsylvania, Philadelphia, PA, 
USA 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Fabrizio 
Tagliavini, MD 
Fondazione IRCCS Istituto Neurologico Carlo 
Besta, Milan, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Jennifer 
C.Thompson, PhD 
Manchester Centre for Clinical Neurosciences, 
Salford Royal NHS Trust, Manchester, UK 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
John 
Q.Trojanowski, 
MD, PhD 
Department of Pathology and Laboratory 
Medicine, Perelman School of Medicine at the 
University of Pennsylvania, Philadelphia, PA, 
USA 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Vivianna M.Van 
Deerlin, MD, PhD 
Department of Pathology and Laboratory 
Medicine, Perelman School of Medicine at the 
University of Pennsylvania, Philadelphia, PA, 
USA 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Julie van der Zee, 
PhD 
Neurodegenerative Brain Diseases group, 
Center for Molecular Neurology, VIB, Antwerp, 
Belgium 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Christine Van 
Broeckhoven, 
PhD, DSc 
Neurodegenerative Brain Diseases group, 
Center for Molecular Neurology, VIB, Antwerp, 
Belgium 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Jeroen G.J. van 
Rooij 
Department of Neurology, Erasmus Medical 
Center, Rotterdam, the Netherlands 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
John C.van 
Swieten, MD, PhD 
Department of Neurology, Erasmus Medical 
Center, Rotterdam, the Netherlands 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Arianna Veronesi, 
MD 
Cognitive Impairment Center, Local Health 
Authority n.2 Marca Trevigiana, Treviso, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Emilia Vitale, PhD 
NeurOMICS laboratory, Institute of 
Biochemistry and Cell Biology (IBBC),CNR 
Napoli, Italy 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Maria L. Waldö, 
MD, PhD 
Division of Clinical Sciences Helsingborg, 
Department of Clinical Sciences Lund, Lund 
University, Lund, Sweden 
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Cathy Woodward Neurogenetics Laboratory, National Hospital for Neurology and Neurosurgery, London, UK 
C9orf72 expansions 
screening; data 
interpretation and drafting of 
manuscript 
Jennifer S. 
Yokoyama, PhD 
Department of Neurology, Memory and Aging 
Center, University of California, San Francisco, 
San Francisco, CA, United States  
Critical review of manuscript 
for intellectual content; 
contribution of samples and 
demographics metadata 
Valentina Escott-
Price, PhD 
Medical Research Council Centre for 
Neuropsychiatric Genetics and Genomics, 
Division of Psychological Medicine and Clinical 
Neurosciences, Cardiff University, UK and 
Dementia Research Institute, Cardiff 
University, Cardiff, UK 
Project design; data 
analyses and interpretation; 
manuscript drafting 
James M. Polke, 
PhD 
Neurogenetics Laboratory, National Hospital 
for Neurology and Neurosurgery, London, UK 
C9orf72 expansions 
screening; data 
interpretation and drafting of 
manuscript 
Raffaele Ferrari, 
PhD 
Department of Neurodegenerative Disease, 
University College London, Institute of 
Neurology, London, UK 
Project design; data 
analyses and interpretation; 
manuscript drafting 
 
  
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 References  
1. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal 
dementia. Neurology 2002;58:1615-1621. 
2. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a 
consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554. 
3. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive 
aphasia and its variants. Neurology 2011;76:1006-1014. 
4. Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - 
frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph 
Lateral Scler Frontotemporal Degener 2017;18:153-174. 
5. Babic Leko M, Zupunski V, Kirincich J, et al. Molecular Mechanisms of 
Neurodegeneration Related to C9orf72 Hexanucleotide Repeat Expansion. Behavioural 
neurology 2019;2019:2909168. 
6. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC 
hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD 
and ALS. Neuron 2011;72:245-256. 
7. Ferrari R, Manzoni C, Hardy J. Genetics and molecular mechanisms of 
frontotemporal lobar degeneration: an update and future avenues. Neurobiology of aging 
2019;78:98-110. 
8. Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: 
overview and what else we can expect from genetic studies. J Neurochem 2016;138 Suppl 
1:32-53. 
9. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and 
pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg 
Psychiatry 2011;82:476-486. 
10. van der Zee J, Gijselinck I, Dillen L, et al. A pan-European study of the C9orf72 repeat 
associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. 
Hum Mutat 2013;34:363-373. 
11. LT T. The Genetics of Monogenic Frontotemporal Dementia. Dement Neuropsychol 
2015:219-229. 
12. Turner MR, Al-Chalabi A, Chio A, et al. Genetic screening in sporadic ALS and FTD. J 
Neurol Neurosurg Psychiatry 2017. 
13. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide 
repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal 
dementia: a cross-sectional study. Lancet Neurol 2012;11:323-330. 
14. Ramos EM, Koros C, Dokuru DR, et al. Frontotemporal dementia spectrum: first 
genetic screen in a Greek cohort. Neurobiology of aging 2019;75:224.e221-224.e228. 
15. Mok K, Traynor BJ, Schymick J, et al. Chromosome 9 ALS and FTD locus is probably 
derived from a single founder. Neurobiology of aging 2012;33:209 e203-208. 
16. Beck J, Poulter M, Hensman D, et al. Large C9orf72 hexanucleotide repeat 
expansions are seen in multiple neurodegenerative syndromes and are more frequent than 
expected in the UK population. American journal of human genetics 2013;92:345-353. 
17. Chiang HH, Forsell C, Lindstrom AK, et al. No common founder for C9orf72 expansion 
mutation in Sweden. J Hum Genet 2017;62:321-324. 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 18. Fratta P, Polke JM, Newcombe J, et al. Screening a UK amyotrophic lateral sclerosis 
cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiology of 
aging 2015;36:546 e541-547. 
19. Xi Z, van Blitterswijk M, Zhang M, et al. Jump from pre-mutation to pathologic 
expansion in C9orf72. American journal of human genetics 2015;96:962-970. 
20. Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C. Genotype-
phenotype links in frontotemporal lobar degeneration. Nat Rev Neurol 2018;14:363-378. 
21. Fournier C, Barbier M, Camuzat A, et al. Relations between C9orf72 expansion size in 
blood, age at onset, age at collection and transmission across generations in patients and 
presymptomatic carriers. Neurobiology of aging 2019;74:234 e231-234 e238. 
22. Gijselinck I, Van Mossevelde S, van der Zee J, et al. The C9orf72 repeat size correlates 
with onset age of disease, DNA methylation and transcriptional downregulation of the 
promoter. Molecular psychiatry 2016;21:1112-1124. 
23. van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association 
between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 
repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013;12:978-
988. 
24. Van Mossevelde S, van der Zee J, Gijselinck I, et al. Clinical Evidence of Disease 
Anticipation in Families Segregating a C9orf72 Repeat Expansion. JAMA Neurol 2017;74:445-
452. 
25. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria 
for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477. 
26. Blauwendraat C, Faghri F, Pihlstrom L, et al. NeuroChip, an updated version of the 
NeuroX genotyping platform to rapidly screen for variants associated with neurological 
diseases. Neurobiology of aging 2017;57:247 e249-247 e213. 
27. Ferrari R, Mok K, Moreno JH, et al. Screening for C9ORF72 repeat expansion in FTLD. 
Neurobiology of aging 2012;33:1850 e1851-1811. 
28. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in 
C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268. 
29. Laaksovirta H, Peuralinna T, Schymick JC, et al. Chromosome 9p21 in amyotrophic 
lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 2010;9:978-985. 
30. Benussi L, Rossi G, Glionna M, et al. C9ORF72 hexanucleotide repeat number in 
frontotemporal lobar degeneration: a genotype-phenotype correlation study. J Alzheimers 
Dis 2015;45:319. 
31. Devenney E, Bartley L, Hoon C, et al. Progression in Behavioral Variant 
Frontotemporal Dementia: A Longitudinal Study. JAMA Neurol 2015;72:1501-1509. 
32. Galimberti D, Fenoglio C, Serpente M, et al. Autosomal dominant frontotemporal 
lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset 
psychotic clinical presentation. Biological psychiatry 2013;74:384-391. 
33. Ramos EM, Dokuru DR, Van Berlo V, et al. Genetic screen in a large series of patients 
with primary progressive aphasia. Alzheimers Dement 2019;15:553-560. 
34. Simon-Sanchez J, Dopper EG, Cohn-Hokke PE, et al. The clinical and pathological 
phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 2012;135:723-735. 
35. Ralph P, Coop G. The geography of recent genetic ancestry across Europe. PLoS 
biology 2013;11:e1001555. 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 36. Warby SC, Montpetit A, Hayden AR, et al. CAG expansion in the Huntington disease 
gene is associated with a specific and targetable predisposing haplogroup. American journal 
of human genetics 2009;84:351-366. 
37. Huang T, Shu Y, Cai YD. Genetic differences among ethnic groups. BMC genomics 
2015;16:1093. 
38. Zhang M, Ferrari R, Tartaglia MC, et al. A C6orf10/LOC101929163 locus is associated 
with age of onset in C9orf72 carriers. Brain 2018;141:2895-2907. 
 
 
 
Acknowledgements 
We thank all patients and their families, whose help and participation made this work 
possible. We thank the IFGC (https://ifgcsite.wordpress.com/) phase-III network. 
AC
CE
PT
ED
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
 Figures legends 
Figure 1. Cohorts (A) and analysis workflow (B). 
AAO = age at onset; logistic/cluster = logistic regression using cluster as covariate; 
logistic/PC1 = logistic regression using PC1 as covariate; Loocv = leave one out 
cross validation regression model; k-fold regression model. 
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Figure 2. Association between AAO and: ancestry; syndrome; expansion length. 
(A): AAO in the group 2 cases. Mean AAO bvFTD (61.7) and PPA (64) (t-test: p = 
1.86x10-5; CI: -3.34--1.25); mean AAO ‘Nordic’ (61.3) and ‘Mediterranean’ (64.3) 
clusters (t-test: p = 1.16x10-7; CI: 1.86-4.03). (B): AAO in the group 3 cases. Mean 
AAO bvFTD (61.7) and PPA (63.5) (t-test: p = 9.1x10-3; CI: -3.11--0.44), mean AAO 
‘Nordic’ (60.9) and ‘Mediterranean’ (64.6) (t-test: p = 2.1x10-7; CI: 2.32-5.09). (C): 
AAO in the group 3 cases. Mean AAO for both ‘no’ and ‘short’ expansions (63.2), for 
‘intermediate’ expansions (61) and for ‘long’ expansions (58) evaluated via ANOVA 
test. 
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Figure 3. Patients subpopulations (bvFTD and PPA syndromes) based on C9orf72 
expansions genetic signatures and ancestry. 
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 Tables 
Table 1. Frequency of expansion carriers in the entire cohort and by syndrome. 
Summary of expansions carriers frequency in the entire cohort (n = 1396) and across 
syndromes. The higher prevalence of expansion carriers in bvFTD vs. the PPA is statistically 
significant: *Fisher’s exact test performed to statistically evaluate the difference between the 
occurrence of pathogenic expansions in the bvFTD vs. the PPA syndromes: p = 2.17x10-5; 
odds ratio (OR) = 6.4; 95% confidence interval (CI): 2.31-24.99. 
 
Cohort n of cases Expansion 
carriers Frequency 
bvFTD 800 40 5%* 
PPA 495 4 0.8%* 
FTLD-MND 101 12 11.9% 
Total 1396 56 4% 
 
 
 
 
Table 2. Frequency of expansion carriers in the ‘Nordic’ and ‘Mediterranean’ clusters. 
The higher prevalence of expansion carriers in the ‘Nordic’ vs. the ‘Mediterranean’ cluster is 
statistically significant: *Fisher’s exact test: p = 1.1x10-2; OR = 2.5; 95% CI: 1.17-5.99. 
 
 
Genetic 
ancestry n of cases 
Expansion 
carriers Frequency 
Nordic 795 35 4.4%* 
Mediterranean 500 9 1.8%* 
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 Table 3. Stratified Fisher’s exact tests comparing prevalence of pathogenic 
expansions across bvFTD and PPA and the ‘Nordic’ and ‘Mediterranean’ clusters. 
P-values presented in the table are corrected for multiple testing statistics. Prior correction p-
values were as follows: * (uncorrected) Fisher’s exact test: p = 4.7x10-3; OR = 2.95; 95% CI: 
1.31-7.52 → significant difference in the prevalence of bvFTD expansion carriers in the 
‘Nordic’ vs. the ‘Mediterranean’ cluster; # (uncorrected) Fisher’s exact test p = 2.7x10-5; OR = 
7.87; 95% CI: 2.43-40.52 → significant difference in the prevalence of expansion carriers in 
bvFTDs vs. PPAs within the Nordic cluster. 
 
 
Subtype/Ancestry Expansion range  
bvFTD pathogenic non-pathogenic Fisher's Exact Test 
Mediterranean 8 323 
Nordic 32 437 p = 1.9x10
-2
* 
        
Ancestry/Subtype Expansion range  
Mediterranean pathogenic non-pathogenic Fisher's Exact Test 
bvFTD 8 323 
PPA 1 168 p = 1 
Nordic       
bvFTD 32 437 
PPA 3 323 p = 1x10
-4#
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